Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

NCT00907517 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelogenous Leukemia, Acute
Leukemia, Lymphocytic, Acute
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Myelogenous Leukemia, Chronic, Aggressive Phase

Interventions

DRUG: MK-8776
DRUG: Cytarabine

Sponsor

Merck Sharp & Dohme LLC